Notch Timing Unlocks Lab-Grown Helper and Killer T Cells for Off-the-Shelf Immunotherapy

TL;DR
UBC researchers show that precisely tuning the duration and intensity of Notch signaling in stem cells can reliably steer them to become helper or killer T cells, enabling scalable, off-the-shelf immunotherapies for cancer and other diseases. This overcomes a long-standing bottleneck by producing both T cell types from renewable sources, potentially reducing manufacturing costs and time.
- Scientists Cracked a Cancer Therapy Problem Doctors Couldn’t Fix Indian Defence Review
- Scientists solve a major roadblock holding back cancer cell therapy ScienceDaily
Want the full story? Read the original reporting
Read on Indian Defence Review